ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Track (GIT) Symptoms in Thailand (GerdQ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00999063
Recruitment Status : Completed
First Posted : October 21, 2009
Last Update Posted : March 31, 2011
Sponsor:
Information provided by:
AstraZeneca

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a prospective , epidemiological, multi-centre, phase IV study, approximately 5,000 patients who suffer with upper gastrointestinal tract symptoms. Each patient will be assessed for GERD with GerdQ Thai Version.

Condition or disease
Upper GIT Symptoms

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Actual Enrollment : 4108 participants
Time Perspective: Prospective
Official Title: Prevalence of GERD in Patients With upperGITsymptoms in Thailand
Study Start Date : December 2009
Actual Primary Completion Date : February 2011
Actual Study Completion Date : February 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: GERD

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Prevalence of gastroesophageal reflux disease (GERD) in patients presented with upper gastrointestinal tract symptoms

Secondary Outcome Measures :
  1. Response to various treatments for patients who have been diagnosed of GERD

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Primary care clinic
Criteria

Inclusion Criteria:

  • Provision of informed consent prior to any study specific procedures
  • Female or male aged at least 18 years
  • Patient must be having symptoms suggestive of upper gastrointestinal tract symptoms such as heart burn/ regurgitation

Exclusion Criteria:

  • Involvement in the planning and /or conduct of the study (applies to both AstraZeneca staff and /or staff at study site
  • Participation in a clinical study(excluding non-interventional study or registry) during the last 3 months
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00999063


Locations
Thailand
Research Site
Bangkok Noi, Bangkok, Thailand
Research Site
Muang, Bangkok, Thailand
Research Site
Pathumwan, Bangkok, Thailand
Research Site
Rajthevee, Bangkok, Thailand
Research Site
Ratchthewi, Bangkok, Thailand
Research Site
Maerim, Chiang Mai, Thailand
Research Site
Maung, Chiang Mai, Thailand
Research Site
Maung, Khon Kaen, Thailand
Research Site
Maung, Nakhon Sri Thammarat, Thailand
Research Site
Maung, Nakhonratchasima, Thailand
Research Site
Maung, Nakhonsawan, Thailand
Research Site
Maung, Nakornpathom, Thailand
Research Site
Muang, Nonthaburi, Thailand
Research Site
Klong Luang, Pathumthani, Thailand
Research Site
Maung, Phetchabun, Thailand
Research Site
Maung, Phuket, Thailand
Research Site
Maung, Rajburi, Thailand
Research Site
Maung, Roiet, Thailand
Research Site
Maung, Samut sakorn, Thailand
Research Site
Maung, Sukhothai, Thailand
Research Site
Maung, Trang, Thailand
Research Site
Maung, Ubonratchathani, Thailand
Research Site
Varin Chamrap, Ubonratchathani, Thailand
Research Site
Muang, Udon Thani, Thailand
Research Site
Maung, Uttaradit, Thailand
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Somchai Leelasukolvong, Dr. Siriraj Hospital
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Sompob Paibulsirijit, MD, Vice President Medical& Regulatory Affairs department, AstraZeneca
ClinicalTrials.gov Identifier: NCT00999063     History of Changes
Other Study ID Numbers: NIS-GTH-NEX-2009/1
First Posted: October 21, 2009    Key Record Dates
Last Update Posted: March 31, 2011
Last Verified: March 2011

Keywords provided by AstraZeneca:
GerdQ

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
 Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases